中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

113例药物性肝损害临床特征及影响因素分析

戴维佳 赖荣陶 王晖 谢青 汤伟亮 庄焱 桂红莲 余敏杰 谢敬东 周慧娟

戴维佳, 赖荣陶, 王晖, 谢青, 汤伟亮, 庄焱, 桂红莲, 余敏杰, 谢敬东, 周慧娟. 113例药物性肝损害临床特征及影响因素分析[J]. 临床肝胆病杂志, 2011, 27(10): 1058-1061+1065.
引用本文: 戴维佳, 赖荣陶, 王晖, 谢青, 汤伟亮, 庄焱, 桂红莲, 余敏杰, 谢敬东, 周慧娟. 113例药物性肝损害临床特征及影响因素分析[J]. 临床肝胆病杂志, 2011, 27(10): 1058-1061+1065.
Dai WeiJia, Lai RongTao, Wang Hui, Xie Qing, Tang WeiLiang, Zhuang Yan, Gui HongLian, Yu MinJie, Xie JingDong, Zhou HuiJuan. The analysis of clinical features and risk factors in 113 patients with drug-induced liver injury[J]. J Clin Hepatol, 2011, 27(10): 1058-1061+1065.
Citation: Dai WeiJia, Lai RongTao, Wang Hui, Xie Qing, Tang WeiLiang, Zhuang Yan, Gui HongLian, Yu MinJie, Xie JingDong, Zhou HuiJuan. The analysis of clinical features and risk factors in 113 patients with drug-induced liver injury[J]. J Clin Hepatol, 2011, 27(10): 1058-1061+1065.

113例药物性肝损害临床特征及影响因素分析

基金项目: 

国家自然科学基金(No:81070334); 上海市科技发展基金(No:10411966800); 中国肝炎防治基金会王宝恩肝纤维化研究基金; 

详细信息
  • 中图分类号: R595.3

The analysis of clinical features and risk factors in 113 patients with drug-induced liver injury

Research funding: 

 

  • 摘要: 目的分析病理诊断为药物性肝损害患者的临床特征及相关影响因素,比较CIOMS/RUCAM和Maria两种评分系统在诊断中的价值。方法选择上海瑞金医院感染科2008年7月~2010年11月经皮肝活组织检查病理诊断为药物性肝损害患者113例,分析年龄、性别、BMI、血清学指标、肝脏组织学改变、患病因素、临床表现及预后,并进行量化评分。结果 113例患者中女性77例,男性36例,平均年龄(47.73±13.17)岁。中药及减肥茶是引起药物性肝损害的主要因素,占48.67%;其余依次为抗微生物药、解热镇痛抗炎药和心血管类药。主要症状为乏力、恶心和上腹不适。临床分型以肝细胞损伤型为主,占47.79%,且女性为主;其余为胆汁淤积型及混合型。停用肝损害药物及对症治疗后,44.25%的患者1个月内肝功能恢复正常。合并自身免疫性肝炎(AIH)患者的纤维化分期评分(F)较高(P=0.015)。炎症活动指数(HAI)≥9且F≥4的患者占6.19%,其中42.86%肝功能异常持续半年以上或死亡。CIOMS/RUCAM评分≥6分占77.88%,Maria评分≥10分占60.18%。结论中药和减肥药是引起药物性肝损...

     

  • [1]Danan G, Benichou C.Causality assessment of adverse reactions to drugs-I.A novel method based on the conclusion ofinternational consensus meetings:application to drug-in-duced fiver injuries[J].Clin Epidemiol, 1993, 46 (11) :1323-1330.
    [2]Maria VA, Victorino RM.Development and validation of a clinicalscale for the diagnosis of drug-induced hepatitis[J].Hepatolo-gy, 1997, 26 (3) :664-669.
    [3]Ishak K, Baptista A, Bianchi L, et al.Histological grading andstaging of chronic hepatitis[J].J Hepatol, 1995, 22 (6) :696-699.
    [4]Benichou C.Criteria of drug-induced liver disorders[J].JHepatol, 1990, 11 (2) :272-276.
    [5]Zimmerman HJ, Ishak KG.General aspects of drug-inducedliver disease[J].Gastroenterol Clin Nort Am, 1995, 24 (4) :739-757.
    [6]Bell LN, Chalasani N.Epidemiology of idiosyncratic drug-in-duced liver injury[J].Semin Liver Dis, 2009, 29 (4) :337-347.
    [7]Chalasani N, Fontana RJ, Bonkovsky HL, et al.Causes, clinical features, and outcomes from a prospective study ofdrug-induced liver injury in the United States[J].Gastro-enterology, 2008, 135 (6) :1924-1934, 1934 e1-4.
    [8]Cotreau MM, von Moltke LL, Greenblatt DJ.The influenceof age and sex on the clearance of cytochrome P450 3A sub-strates[J].Clin Pharmacokinet, 2005, 44 (1) :33-60.
    [9]Kazutot T, Yukihiros S.Practical guidelines for diagnosis andearly management of drug-induced liver injury[J].World JGastroenterol, 2008, 14 (44) :6774-6785.
  • 加载中
计量
  • 文章访问数:  294
  • HTML全文浏览量:  15
  • PDF下载量:  352
  • 被引次数: 0
出版历程
  • 出版日期:  2011-10-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回